Resultados de investigaciones españolas trasladados a la clínica

nbt0415-323-I1
Recently they published the first results in patients with drug Abemaciclib, a selective inhibitor of Cdk4 and Cdk6 high antitumor activity in patients cancers.

La importancia de Cdk4 en cáncer fue descrita por el Dr. Barbacid en 2010 thanks to studies conducted in preclinical models of lung cancer, where it was observed as the selective inhibition of Cdk4 in these non small cell tumors possessing oncogenic mutation in Kras significant regression of cancer it was produced by activation of senescence in tumor cells.

So, Dr. Barbacid has promoted clinical trials in patients, as recently described in the journal Cancer abemaciclib Discovery. Ambemaciclib is a small molecule that inhibits Cdk4 and Cdk6 having a high selectivity for Cdk4, so it is able to inhibit the phosphorylation of RB and cause arrest of cells in G1.
La administración continuada de este fármaco cuando es administrado de forma única demuestra una actividad clínica prolongada en 225 patients who were treated within a clinical phase I trial with cancer tumors NSCLC, glioblastoma y melanoma. They are also very interesting as lung cancer patients responded better to therapy with abemaciclib were those who had mutations in the Kras oncogene, as well he had proposed Dr. Barbacid en su artículo de Cancer Cell en 2010.